Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of AD-213-B vs AD-2132 in Healthy Adults
NCT04755985Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-213-B in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area Under the Curve Over the Dosing Interval and Change of Integrated Gastric Acidity from Baseline. Started Mar 2021; status: completed.
02
Drugs
AD-213-B
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04755985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755985.